Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014781 · ClinicalTrials.gov registry record
Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis
A clinical trial, sponsored by University of Utah.
- Completed
- Registry status
- 39
- Enrollment target
NCT00014781: Completed study, sponsored by University of Utah.
NCT00014781 is a clinical trial that has completed, run by University of Utah. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00014781 has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- 39 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Determine the amount of hepatic glucose production derived from gluconeogenesis and glycogenolysis in the post-absorptive state in patients with cystic fibrosis. II. Determine de novo lipogenesis in relationship to resting energy expenditure in this patient population.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2001-02 |
What the finished NCT00014781 record still lists
NCT00014781 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00014781 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00014781 about?
NCT00014781 is a clinical study titled "Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis". OBJECTIVES: I. Determine the amount of hepatic glucose production derived from gluconeogenesis and glycogenolysis in the post-absorptive state in patients with cystic fibrosis. II. Determine de novo lipogenesis in relationship to resting energy expenditure in this patient population.
What is the current status of trial NCT00014781?
This trial is currently completed. The enrollment target is 39 participants. The study started on 2001-02.
Who is sponsoring clinical trial NCT00014781?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia